Opinion
Video
Exploring Therapeutic Avenues in HER2+ Breast Cancer
Experts delve into post–KATHERINE trial discussions, examining data and its impact on residual disease. They highlight unmet needs, emphasizing the ongoing CompassHER2 RD trial’s potential to address challenges, especially regarding brain metastases.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy and Rugo discuss the potential of neratinib in addressing residual disease after T-DM1 treatment in patients with HER2-positive breast cancer. The external study showed positive results, especially in patients who are estrogen-receptor positive, highlighting the need for additional therapies to prevent metastasis. O’Shaughnessy acknowledges the ongoing CompassHER2 RD trial’s aim to reduce the risk of brain metastasis by combining T-DM1 (trastuzumab emtansine) with tucatinib. Isaacs stresses the importance of enrolling patients in trials targeting brain metastases, aiming for better standards of care. The discussion emphasizes the optimization of endocrine therapy for HER2-positive patients and ongoing efforts to improve treatment strategies in both adjuvant and metastatic settings.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
